focus -WSS

focus

author：leisure time 2025-08-11 02:16:09 - browse：57

De-Shaine Murray is working at the cutting edge of neurotechnology. As a postdoctoral fellow at Yale, he is developing a device to monitor the brain following traumatic brain injury or stroke.

He is also trying to fight the long legacy of racism in neuroscience. During 2020, when it was difficult to conduct research, he said, “I got the chance and the ability to read more widely and to just look into the legacy of neuroscience.” He found a direct line from racist pseudoscience like phrenology to disparities in neuroscience today, like how the texture of Black people’s hair can sometimes exclude them from clinical trials because electrodes are not designed for them. In 2021, he co-founded Black in Neuro, an organization dedicated to improving Black representation in neuroscience.

On this episode of the “First Opinion Podcast,” I spoke to him about how the past and present racism in neuroscience could be reflected in the future, especially as neurotechnology like brain implants become more common.

“I’m not saying that whatever electrode that you made or created is racist. But when you have someone who … creates a technology but doesn’t think about the wide range of users that are potentially going to use it, then that’s where the problem comes in,” he told me.

We also discussed the way inequities in neuroscience research are visible in stroke wards, how brain implants might jump from helping disabled people to being used for human enhancement, and more.

Our conversation was inspired by his recent First Opinion essay, “Neuroscience has to grapple with a long legacy of racism if it wants to move into the future.” The book I mention at the end is “Lock In” by John Scalzi, a great sci-fi mystery exploring themes of race, socioeconomic status, neurotechnology, and more.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

LETTER TO THE EDITOR

Have an opinion on this essay? Submit a letter to the editor here.

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： What drug price negotiations mean for Medicare Part D

leisure time

WSS

Medicare Advantage coverage denials need scrutiny, senators say

Medicare Advantage coverage denials need scrutiny, senators say

American taxpayers paid $1.8 trillion in health care costs in 2022

How to fix cancer clinical trials' diversity problem

Weighted lottery helped low

At JPM 2024, hospital systems pitch financial strength to investors

leisure time

focus

LETTER TO THE EDITOR

Have an opinion on this essay? Submit a letter to the editor here.

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Merck to acquire Harpoon Therapeutics for $680 million

Apple is now the first public company to be valued at $3 trillion

A preacher's new calling: Diversifying neuroscience research

Medicare proposal to cover medical devices draws a mixed reaction

Stories you might have missed in 2023: health, science, medicine

Cancer drug shortages should be causing more outrage

A new House health package & hospitals’ new site

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Boston Scientific acquires urology company Axonics for $3.7 billion

leisure time

House transparency, PBM reform bill gains bipartisan support

The (many) problems with a new study criticizing cancer screening

Nonprofit, backed by Microsoft, to certify AI tools in health care

What drug price negotiations mean for Medicare Part D

How to protect patients from sexual assault

Ascension's ugly legal battle over care for poor patients in Texas

Wikipedia

entertainment

leisure time

focus